Castle Biosciences, Inc. (CSTL)

Market Cap	1.15B
Revenue (ttm)	343.53M
Net Income (ttm)	-12.24M
Shares Out	29.19M
EPS (ttm)	-0.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	183,714
Open	39.89
Previous Close	40.09
Day's Range	39.28 - 39.97
52-Week Range	14.59 - 42.18
Beta	1.14
Analysts	Strong Buy
Price Target	42.83 (+8.72%)
Earnings Date	Nov 3, 2025

About CSTL

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose me...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 25, 2019
• Employees: 761
• Stock Exchange: NASDAQ
• Ticker Symbol: CSTL
• Website: https://castlebiosciences.com

Analyst Summary

According to 6 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price target is $42.83, which is an increase of 8.72% from the latest price.

Price Target

$42.83

(8.72% upside)

Analyst Consensus: Strong Buy